Cancer tests scale further as new product launches begin
- Q2 2026 testing revenue reached $145.7 million, a 19% year-over-year increase.
- Diagnostic test volume grew 14% in the second quarter.
- The company officially launched its TrueMRD and Prosigna LDT tests in the U.S. market.
- Testing revenue makes up nearly 97% of total sales, placing heavy reliance on payer coverage.
- Execution risk now shifts from clinical development to commercial adoption for the newly launched tests.
A stronger core with a higher bar
Veracyte continues to deliver clear momentum. In Q2 2026, testing revenue rose 19% year-over-year to $145.7 million, and diagnostic test volume grew 14%. That is strong proof that the main business is still gaining use among doctors and holding a durable growth trajectory.
The bull case is simple. Veracyte has built a testing flywheel. They publish clinical evidence, get into medical guidelines, win payer coverage, and then sell more tests through the same doctor network. That model is now producing real profit and cash, moving the company from an anticipated growth story into clear commercial execution.
The hard part is that the stock has already priced in these better results. The next leg of growth depends on newer tests, specifically Prosigna in U.S. breast cancer and TrueMRD in muscle-invasive bladder cancer, which were both launched in Q2 2026.
Since the Q2 filing, Veracyte has transitioned from waiting on these catalysts to active commercial launch mode. The key watch item now is not whether the products work, but whether doctors order them, payers reimburse them, and early sales prove that they can become significant revenue engines.
Evidence turns into paid tests
Veracyte makes money when doctors order its cancer tests and payers, such as Medicare or private insurers, agree to pay for them. Most revenue comes from U.S. laboratory developed tests, which are diagnostic tests designed and run inside a certified lab.
The business works best when clinical data shows that a test changes patient care. Decipher Prostate is the clearest example. Solid evidence and guideline inclusion help doctors trust the test, which raises overall volume. Better payer contracts and clear billing can also raise the average selling price, which is the actual cash collected per test.
This model can break in two places. Doctors may not adopt a new test if they do not trust the science. Or payers may refuse coverage, demand prior approval, or cut payment rates. Because testing is nearly all of total revenue, reimbursement is the central pillar of the company.
Veracyte also has a useful sales base. Its urology channel already sells Decipher Prostate, and that same channel helps launch Decipher Bladder and TrueMRD. That lowers some initial launch risk, but it does not remove the need for favorable coverage decisions and proof of repeat ordering.
Core tests fund new bets
Decipher Prostate
This is the main growth driver. It continues to show strong traction in higher-risk prostate cancer categories.
Afirma
Afirma helps evaluate thyroid nodules and remains a steady second pillar for the company with durable volume growth.
Decipher Bladder
This is an earlier bladder cancer test with growing adoption. It helps Veracyte build deeper ties with urologists as TrueMRD scales.
Prosigna IVD
Prosigna is sold outside the U.S. as a test kit used by local labs. Product revenue is much smaller than testing revenue.
Prosigna LDT
Now officially launched in the U.S., this breast cancer test is a major growth option. It depends on clinical evidence and share gains against established rivals.
TrueMRD
Now commercially launched for muscle-invasive bladder cancer, TrueMRD looks for small signs that cancer may be returning. It relies on the existing urology sales channel.
Almost entirely a testing business
The mix uses Q2 2026 revenue. Testing makes up nearly 97% of revenue, so Decipher and Afirma carry almost all of the current financial results.
What could break the story
New launches fail to scale
High impact · Medium oddsThe stock expects Prosigna LDT and TrueMRD to add meaningful growth beyond the core Decipher and Afirma products. If early ordering is slow, future growth expectations could fall. Favorable launch headlines are not enough if doctors do not change their ordering habits.
Reimbursement pressure
High impact · Medium oddsVeracyte recognizes testing revenue based on what it expects to collect, not the list price. A negative coverage change from Medicare, more strict prior authorization requirements, or lower payment rates could hurt revenue and margin immediately.
Core growth slows
Medium impact · Medium oddsThe company relies heavily on double-digit growth from its legacy products. If the core tests cool down at the same time new products ramp slowly, the overall growth profile can fade quickly.
LDT regulation adds cost and delay
Medium impact · Medium oddsThe FDA rule issued in 2024 phases out broad enforcement discretion for many laboratory developed tests over four years. While existing tests may have some protection, newer tests could face more stringent review. That can raise costs and stretch future launch timelines.
MRD competition and IP fights
Medium impact · Medium oddsThe minimal residual disease market is highly competitive and legally active. Veracyte names Natera as a main competitor. If rivals win doctors faster or intellectual property disputes limit the whole-genome approach, TrueMRD upside could shrink.
Israel operating risk
Medium impact · Low oddsThe past acquisition of C2i Genomics gave Veracyte significant operations in Israel. The company warns that geopolitical conflict in the Middle East could interrupt or suspend that site without warning. This matters most for TrueMRD development.
In one breath
What does Veracyte actually sell?
Veracyte sells genomic cancer tests. These tests read patterns in tumor or tissue samples to help doctors decide whether a patient needs more treatment, can avoid treatment, or may have cancer returning.
Why is Decipher important to Veracyte?
Decipher Prostate is the company's main growth engine. It benefits from clinical evidence, medical guideline support, and a growing base of doctors ordering it for prostate cancer treatment decisions.
Why does reimbursement matter so much?
Most Veracyte revenue comes from tests that need payment from Medicare, insurers, or patients. If payers cut rates or deny more claims, revenue and profit can fall even when doctors order tests.
Is Veracyte profitable now?
Yes, recent quarters have shown strong profitability and positive cash from operations. The main question is whether that level holds while the company invests heavily in marketing TrueMRD and Prosigna.
